位置:首页 > 蛋白库 > NMNA2_BOVIN
NMNA2_BOVIN
ID   NMNA2_BOVIN             Reviewed;         307 AA.
AC   Q0VC59;
DT   08-APR-2008, integrated into UniProtKB/Swiss-Prot.
DT   05-SEP-2006, sequence version 1.
DT   03-AUG-2022, entry version 117.
DE   RecName: Full=Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 2 {ECO:0000305};
DE            Short=NMN/NaMN adenylyltransferase 2;
DE            EC=2.7.7.1 {ECO:0000250|UniProtKB:Q9BZQ4};
DE            EC=2.7.7.18 {ECO:0000250|UniProtKB:Q9BZQ4};
DE   AltName: Full=Nicotinamide mononucleotide adenylyltransferase 2;
DE            Short=NMN adenylyltransferase 2;
DE   AltName: Full=Nicotinate-nucleotide adenylyltransferase 2;
DE            Short=NaMN adenylyltransferase 2;
GN   Name=NMNAT2;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Laurasiatheria; Artiodactyla; Ruminantia; Pecora; Bovidae;
OC   Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=Hereford; TISSUE=Brain cortex;
RG   NIH - Mammalian Gene Collection (MGC) project;
RL   Submitted (AUG-2006) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Nicotinamide/nicotinate-nucleotide adenylyltransferase that
CC       acts as an axon maintenance factor (By similarity). Catalyzes the
CC       formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. Can
CC       also use the deamidated form; nicotinic acid mononucleotide (NaMN) as
CC       substrate but with a lower efficiency. Cannot use triazofurin
CC       monophosphate (TrMP) as substrate. Also catalyzes the reverse reaction,
CC       i.e. the pyrophosphorolytic cleavage of NAD(+). For the
CC       pyrophosphorolytic activity prefers NAD(+), NADH and NaAD as substrates
CC       and degrades nicotinic acid adenine dinucleotide phosphate (NHD) less
CC       effectively. Fails to cleave phosphorylated dinucleotides NADP(+),
CC       NADPH and NaADP(+) (By similarity). Axon survival factor required for
CC       the maintenance of healthy axons: acts by delaying Wallerian axon
CC       degeneration, an evolutionarily conserved process that drives the loss
CC       of damaged axons (By similarity). {ECO:0000250|UniProtKB:Q8BNJ3,
CC       ECO:0000250|UniProtKB:Q9BZQ4}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + beta-nicotinamide D-ribonucleotide + H(+) = diphosphate
CC         + NAD(+); Xref=Rhea:RHEA:21360, ChEBI:CHEBI:14649, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:33019, ChEBI:CHEBI:57540; EC=2.7.7.1;
CC         Evidence={ECO:0000250|UniProtKB:Q9BZQ4};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:21361;
CC         Evidence={ECO:0000250|UniProtKB:Q9BZQ4};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:21362;
CC         Evidence={ECO:0000250|UniProtKB:Q9BZQ4};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H(+) + nicotinate beta-D-ribonucleotide = deamido-NAD(+)
CC         + diphosphate; Xref=Rhea:RHEA:22860, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:33019, ChEBI:CHEBI:57502,
CC         ChEBI:CHEBI:58437; EC=2.7.7.18;
CC         Evidence={ECO:0000250|UniProtKB:Q9BZQ4};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:22861;
CC         Evidence={ECO:0000250|UniProtKB:Q9BZQ4};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:22862;
CC         Evidence={ECO:0000250|UniProtKB:Q9BZQ4};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:Q9BZQ4};
CC       Note=Divalent metal cations. Mg(2+) confers the highest activity.
CC       {ECO:0000250|UniProtKB:Q9BZQ4};
CC   -!- ACTIVITY REGULATION: Inhibited by P1-(adenosine-5')-P3-(nicotinamide-
CC       riboside-5')-triphosphate (Np3AD) and P1-(adenosine-5')-P4-
CC       (nicotinamide-riboside-5')-tetraphosphate (Np4AD).
CC       {ECO:0000250|UniProtKB:Q9BZQ4}.
CC   -!- PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from
CC       nicotinamide D-ribonucleotide: step 1/1.
CC       {ECO:0000250|UniProtKB:Q9BZQ4}.
CC   -!- PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; deamido-NAD(+)
CC       from nicotinate D-ribonucleotide: step 1/1.
CC       {ECO:0000250|UniProtKB:Q9BZQ4}.
CC   -!- SUBUNIT: Monomer. {ECO:0000250|UniProtKB:Q9BZQ4}.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane
CC       {ECO:0000250|UniProtKB:Q8BNJ3}; Lipid-anchor
CC       {ECO:0000250|UniProtKB:Q8BNJ3}. Cytoplasmic vesicle membrane
CC       {ECO:0000250|UniProtKB:Q8BNJ3}; Lipid-anchor
CC       {ECO:0000250|UniProtKB:Q8BNJ3}. Cytoplasm
CC       {ECO:0000250|UniProtKB:Q9BZQ4}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:Q8BNJ3}. Note=Delivered to axons with Golgi-
CC       derived cytoplasmic vesicles. {ECO:0000250|UniProtKB:Q8BNJ3}.
CC   -!- PTM: Degraded in response to injured neurite. Degradation is probably
CC       caused by ubiquitination by MYCBP2 (By similarity). Ubiquitinated on
CC       threonine and/or serine residues by MYCBP2; consequences of threonine
CC       and/or serine ubiquitination are however unclear (By similarity).
CC       {ECO:0000250|UniProtKB:Q8BNJ3, ECO:0000250|UniProtKB:Q9BZQ4}.
CC   -!- PTM: Palmitoylated; palmitoylation is required for membrane
CC       association. {ECO:0000250|UniProtKB:Q8BNJ3}.
CC   -!- SIMILARITY: Belongs to the eukaryotic NMN adenylyltransferase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC120344; AAI20345.1; -; mRNA.
DR   RefSeq; NP_001068954.1; NM_001075486.1.
DR   RefSeq; XP_015330742.1; XM_015475256.1.
DR   AlphaFoldDB; Q0VC59; -.
DR   SMR; Q0VC59; -.
DR   STRING; 9913.ENSBTAP00000001052; -.
DR   PaxDb; Q0VC59; -.
DR   Ensembl; ENSBTAT00000001052; ENSBTAP00000001052; ENSBTAG00000000795.
DR   GeneID; 511042; -.
DR   KEGG; bta:511042; -.
DR   CTD; 23057; -.
DR   VEuPathDB; HostDB:ENSBTAG00000000795; -.
DR   VGNC; VGNC:32133; NMNAT2.
DR   eggNOG; KOG3199; Eukaryota.
DR   GeneTree; ENSGT00950000183179; -.
DR   HOGENOM; CLU_033366_1_0_1; -.
DR   InParanoid; Q0VC59; -.
DR   OMA; VNHPMSI; -.
DR   OrthoDB; 1308027at2759; -.
DR   TreeFam; TF315035; -.
DR   UniPathway; UPA00253; UER00332.
DR   UniPathway; UPA00253; UER00600.
DR   Proteomes; UP000009136; Chromosome 16.
DR   Bgee; ENSBTAG00000000795; Expressed in prefrontal cortex and 104 other tissues.
DR   ExpressionAtlas; Q0VC59; baseline.
DR   GO; GO:0030424; C:axon; IEA:UniProtKB-SubCell.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IBA:GO_Central.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0000309; F:nicotinamide-nucleotide adenylyltransferase activity; IBA:GO_Central.
DR   GO; GO:0004515; F:nicotinate-nucleotide adenylyltransferase activity; IBA:GO_Central.
DR   GO; GO:0009435; P:NAD biosynthetic process; IBA:GO_Central.
DR   CDD; cd09286; NMNAT_Eukarya; 1.
DR   Gene3D; 3.40.50.620; -; 1.
DR   InterPro; IPR004821; Cyt_trans-like.
DR   InterPro; IPR045094; NMNAT_euk.
DR   InterPro; IPR014729; Rossmann-like_a/b/a_fold.
DR   Pfam; PF01467; CTP_transf_like; 1.
PE   2: Evidence at transcript level;
KW   ATP-binding; Cell projection; Cytoplasm; Cytoplasmic vesicle;
KW   Golgi apparatus; Lipoprotein; Membrane; NAD; Nucleotide-binding;
KW   Nucleotidyltransferase; Palmitate; Pyridine nucleotide biosynthesis;
KW   Reference proteome; Transferase; Ubl conjugation.
FT   CHAIN           1..307
FT                   /note="Nicotinamide/nicotinic acid mononucleotide
FT                   adenylyltransferase 2"
FT                   /id="PRO_0000328660"
FT   BINDING         15..17
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q96T66"
FT   BINDING         24
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q96T66"
FT   BINDING         55..57
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q96T66"
FT   BINDING         92..95
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q96T66"
FT   BINDING         200..202
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q96T66"
FT   BINDING         212..213
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q96T66"
FT   BINDING         271..274
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q96T66"
FT   LIPID           164
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BNJ3"
FT   LIPID           165
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BNJ3"
SQ   SEQUENCE   307 AA;  34468 MW;  0E037406187B85DF CRC64;
     MTETTKTHVI LLACGSFNPI TKGHIQMFER ARDYLHKTGR FIVIGGIVSP VHDSYGKQGL
     VSSRHRLIMC QLAVQNSDWI RVDPWECYQD TWQTTCSVLE HHRDLMKRVT GCILSNVNTP
     SMTPVIGQPR NETSQPIYQN NNAPSKPTAA KILGKVGESL SRICCVRPPV ERFTFVDENA
     NLGTVMRYEE IELRILLLCG SDLLESFCIP GLWNEADMEV IVGDFGIVVV PRDAADTDRI
     MNHSSILRKY KNNIMVVKDD INHPMSVVSS TKSRLALQHG DGHVVDYLSQ PVIDYILKSQ
     LYINASG
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024